Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Primary Sjögren's Syndrome
Interventions: AMG 557/MEDI5872, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: San Francisco, California • Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: Acute Pain
Interventions: VX-993, HB/APAP, Placebo (matched to VX-993), Placebo (matched to HB/APAP); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more

Conditions: Suicide Prevention
Interventions: " Safer Still " Interactive Intervention, Enhanced Usual Care (EUC):; Behavioral · Other
Lead sponsor: Jeff Bridge; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Hot Flashes, Prostate Cancer
Interventions: oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill; Dietary Supplement · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Vilazodone; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 38
States / cities: Beverly Hills, California • Chino, California • Costa Mesa, California + 32 more

Conditions: Dry Eye Syndrome
Interventions: EBI-005-2; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 8
States / cities: Artesia, California • Ranchero Cordova, California • Torrence, California + 5 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 7 more

Conditions: Methodology Study
Interventions: placebo, zolpidem; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Keratoconus
Interventions: GLK-221 Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Westerville, Ohio

Conditions: Male Pattern Hair Loss
Interventions: HST 001, Phosphate Buffered Saline; Biological · Other
Lead sponsor: Histogen; Industry
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Malignant Solid Tumor
Interventions: Ifetroban Sodium, Placebo; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Psychosis, Dementia, Aggression, Agitation, Alzheimer Dementia
Interventions: MP-101, Placebo; Drug
Lead sponsor: Mediti Pharma Inc.; Other
Eligibility: 50 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 17
States / cities: Phoenix, Arizona • Pasadena, California • Fairfield, Connecticut + 14 more

Conditions: Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions: Denosumab, Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 30 Years to 120 Years · Male only
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 52
States / cities: Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more

Conditions: Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions: Placebo, Rifaximin; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 35 Years to 72 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions: oxaliplatin, leucovorin calcium, fluorouracil, placebo, vismodegib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 30
States / cities: Sacramento, California • Chicago, Illinois • Decatur, Illinois + 16 more

Conditions: Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions: VS-041, Placebo; Drug · Other
Lead sponsor: Vasa Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Little Rock, Arkansas • Huntington Beach, California • Santa Maria, California + 18 more

Conditions: Obesity, Overweight
Interventions: HPP404, Placebo; Drug
Lead sponsor: High Point Pharmaceuticals, LLC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Augusta, Georgia • Valparaiso, Indiana • Louisville, Kentucky + 7 more

Conditions: Healthy
Interventions: L-Ergothioneine 10 mg/d, L-Ergothioneine 25 mg/d, Placebo; Dietary Supplement · Other
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 55 Years to 79 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 3 Years to 6 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson Disease
Interventions: Spheramine (BAY86-5280), Placebo; Biological · Procedure
Lead sponsor: Bayer; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 7 more

Conditions: Migraine Disorders, Headache Disorders
Interventions: SPN-538, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy
Interventions: Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet; Behavioral · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 55 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2031
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo for dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 36
States / cities: Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more

Conditions: Puberty, Hyperandrogenism
Interventions: Micronized progesterone suspension, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

Safer Still (Exploratory Project 3)

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

Safety and Efficacy of Vilazodone in Major Depressive Disorder

A Multi-Center Study Subjects With Dry Eye Syndrome

A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1

Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Gulf War Digestive Health Study

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects

Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

STEPS Trial - Spheramine Safety and Efficacy Study

Therapy for Migraine Prevention in Children 6-11 Years of Age

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism